Patients were randomly assigned 1:1 to receive ipilimumab at 10 mg/kg plus dacarbazine ( n = 250 ) or placebo plus dacarbazine ( n = 252 ) at weeks 1 , 4 , 7 , and 10 followed by dacarbazine alone every 3 weeks through week 22 .